BRPI0921802A8 - uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. - Google Patents

uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.

Info

Publication number: BRPI0921802A8
Authority: BR; Brazil
Prior art keywords: inhibitor; pi3k; phosphatidylinositol; kinase; combination
Prior art date: 2008-10-31

Application number

BRPI0921802A

Other languages

English (en)

Inventor

Garcia-Echeverria Carlos

Maira Sauveur-Michel

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-31

Filing date

2009-10-29

Publication date

2018-03-13

2009-10-29 Application filed by Novartis Ag filed Critical Novartis Ag

2016-09-27 Publication of BRPI0921802A2 publication Critical patent/BRPI0921802A2/pt

2018-03-13 Publication of BRPI0921802A8 publication Critical patent/BRPI0921802A8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0921802A 2008-10-31 2009-10-29 uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. BRPI0921802A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08168044		2008-10-31
PCT/EP2009/064274 WO2010049481A1 (en)	2008-10-31	2009-10-29	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Publications (2)

Publication Number	Publication Date
BRPI0921802A2 BRPI0921802A2 (pt)	2016-09-27
BRPI0921802A8 true BRPI0921802A8 (pt)	2018-03-13

Family

ID=40332588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921802A BRPI0921802A8 (pt)	2008-10-31	2009-10-29	uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.

Country Status (12)

Country	Link
US (3)	US20110195966A1 (pt)
EP (1)	EP2349275B1 (pt)
JP (4)	JP2012506898A (pt)
KR (1)	KR20110090911A (pt)
CN (2)	CN102202668A (pt)
AU (1)	AU2009309616B2 (pt)
BR (1)	BRPI0921802A8 (pt)
CA (1)	CA2736361C (pt)
ES (1)	ES2627677T3 (pt)
MX (1)	MX2011004585A (pt)
RU (2)	RU2538683C2 (pt)
WO (1)	WO2010049481A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100048912A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
US20120064143A1 (en)	2008-11-11	2012-03-15	The Board Of Regents Of The University Of Texas System	Inhibition of mammalian target of rapamycin
AU2010210422A1 (en)	2009-02-05	2011-08-18	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
GB2478556A (en) *	2010-03-09	2011-09-14	Myrovlytis Technology Ventures Ltd	A composition for use in the treatment of Birt-Hogg-Dubô sydrome
EP2675450B1 (en) *	2011-02-16	2016-02-10	Novartis AG	Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
TWI592411B (zh) *	2011-02-23	2017-07-21	英特爾立秦有限責任公司	激酶抑制劑之組合及其用途
CN103619873A (zh) *	2011-03-07	2014-03-05	泰莱托恩基金会	Tfeb变体及其应用
NZ615593A (en) *	2011-04-25	2015-05-29	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
CN103703174B (zh) *	2011-05-04	2017-05-10	因特利凯有限责任公司	联合药物组合物及其用途
TWI547493B (zh)	2011-09-27	2016-09-01	諾華公司	作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮
CA2854926A1 (en) *	2011-11-08	2013-05-16	Intellikine, Llc	Treatment regimens using multiple pharmaceutical agents
US20130209543A1 (en) *	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
UY34632A (es) *	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2012112128A (ru) *	2012-03-29	2013-10-10	Холин Максим Николаевич	ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
ES2665619T3 (es)	2013-03-14	2018-04-26	Novartis Ag	3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
EP4066841A1 (en)	2013-03-14	2022-10-05	University of Maryland, Baltimore	Androgen receptor down-regulating agents and uses thereof
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MY182082A (en) *	2013-05-01	2021-01-18	Hoffmann La Roche	Biheteroaryl compounds and uses thereof
KR20160058774A (ko)	2013-08-12	2016-05-25	토카이 파마슈티컬, 아이엔씨.	안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN103483345B (zh) *	2013-09-25	2016-07-06	中山大学	Pi3k激酶抑制剂、包含其的药物组合物及其应用
ES2900426T3 (es)	2013-12-31	2022-03-16	Rapamycin Holdings Llc	Preparaciones orales y uso de nanopartículas de rapamicina
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
EP3708680B8 (en) *	2015-04-15	2023-08-30	University of Massachusetts	Compositions and methods for xi chromosome reactivation
MX2017014776A (es)	2015-05-20	2018-02-15	Novartis Ag	Combinacion farmaceutica de everolimus con dactolisib.
EP3544608A1 (en)	2016-11-23	2019-10-02	Novartis AG	Methods of enhancing immune response with everolimus, dactolisib or both
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
KR20210158019A (ko)	2020-06-23	2021-12-30	주식회사 온코빅스	포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
CN112294967A (zh) *	2020-09-30	2021-02-02	四川大学	一种mTOR抑制剂与抗癌药物的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK18362002A3 (sk) *	2000-06-26	2004-02-03	Stressgen Biotechnologies Corporation	Použitie prostriedku s obsahom fúzneho proteínu
MX2007004489A (es) *	2004-10-13	2007-09-21	Wyeth Corp	Analogos de 17-hidroxiwortamina como inhibidores pi3k.
WO2007010012A2 (en) *	2005-07-20	2007-01-25	Novartis Ag	Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
KR101464384B1 (ko) *	2005-11-22	2014-11-21	쿠도스 파마슈티칼스 리미티드	ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
JP5156644B2 (ja) *	2006-01-25	2013-03-06	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	不飽和ｍＴＯＲ阻害剤
WO2007120897A2 (en) *	2006-04-13	2007-10-25	The Trustees Of Columbia University In The City Of New York	Compositions and intraluminal devices for inhibiting vascular stenosis
ATE551334T1 (de) *	2007-02-06	2012-04-15	Novartis Ag	Pi3-kinase-hemmer und verfahren zu ihrer verwendung
CN101616672A (zh) *	2007-02-20	2009-12-30	诺瓦提斯公司	作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
CN101896177A (zh) *	2007-12-13	2010-11-24	诺瓦提斯公司	用于治疗癌症的治疗剂的组合

2009
- 2009-10-29 EP EP09744391.5A patent/EP2349275B1/en not_active Not-in-force
- 2009-10-29 CN CN2009801431736A patent/CN102202668A/zh active Pending
- 2009-10-29 ES ES09744391.5T patent/ES2627677T3/es active Active
- 2009-10-29 MX MX2011004585A patent/MX2011004585A/es active IP Right Grant
- 2009-10-29 AU AU2009309616A patent/AU2009309616B2/en not_active Ceased
- 2009-10-29 KR KR1020117009771A patent/KR20110090911A/ko not_active Ceased
- 2009-10-29 RU RU2011121508/15A patent/RU2538683C2/ru not_active IP Right Cessation
- 2009-10-29 WO PCT/EP2009/064274 patent/WO2010049481A1/en not_active Ceased
- 2009-10-29 BR BRPI0921802A patent/BRPI0921802A8/pt not_active IP Right Cessation
- 2009-10-29 CA CA2736361A patent/CA2736361C/en not_active Expired - Fee Related
- 2009-10-29 JP JP2011533721A patent/JP2012506898A/ja not_active Withdrawn
- 2009-10-29 US US13/123,956 patent/US20110195966A1/en not_active Abandoned
- 2009-10-29 CN CN201510402018.9A patent/CN105030784A/zh active Pending
2014
- 2014-04-15 RU RU2014115188/15A patent/RU2014115188A/ru not_active Application Discontinuation
- 2014-09-05 JP JP2014181069A patent/JP2015013883A/ja not_active Withdrawn
2015
- 2015-11-24 US US14/950,869 patent/US20160136175A1/en not_active Abandoned
2016
- 2016-07-06 JP JP2016134514A patent/JP2017002058A/ja not_active Ceased
2018
- 2018-01-16 US US15/872,043 patent/US20180133226A1/en not_active Abandoned
- 2018-07-20 JP JP2018136756A patent/JP2018197243A/ja active Pending

Also Published As

Publication number	Publication date
US20110195966A1 (en)	2011-08-11
JP2018197243A (ja)	2018-12-13
CA2736361A1 (en)	2010-05-06
AU2009309616A1 (en)	2010-05-06
RU2011121508A (ru)	2012-12-10
WO2010049481A1 (en)	2010-05-06
MX2011004585A (es)	2011-06-01
AU2009309616B2 (en)	2014-02-13
JP2015013883A (ja)	2015-01-22
ES2627677T3 (es)	2017-07-31
AU2009309616A2 (en)	2011-07-07
EP2349275A1 (en)	2011-08-03
EP2349275B1 (en)	2017-03-08
US20160136175A1 (en)	2016-05-19
CA2736361C (en)	2017-10-10
CN102202668A (zh)	2011-09-28
US20180133226A1 (en)	2018-05-17
RU2538683C2 (ru)	2015-01-10
KR20110090911A (ko)	2011-08-10
JP2012506898A (ja)	2012-03-22
JP2017002058A (ja)	2017-01-05
CN105030784A (zh)	2015-11-11
BRPI0921802A2 (pt)	2016-09-27
RU2014115188A (ru)	2015-10-20

Publication	Publication Date	Title
BRPI0921802A8 (pt)	2018-03-13	uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
BRPI0809239A2 (pt)	2014-11-25	Análogos de pirazolopirimidina e seu uso como inibidores de quinase mtor e quinase p13
BRPI0815979A2 (pt)	2017-06-13	compostos e composições com inibidores de quinase, bem como uso dos mesmos
BRPI0907036A2 (pt)	2015-07-07	Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BRPI0918502A2 (pt)	2015-12-01	aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BR112012003842A2 (pt)	2016-03-22	composição farmacêutica, método de formulação e uso da mesma
BRPI0921389A2 (pt)	2018-06-19	seringa de um só uso, de inutilização automática
BRPI1008498A2 (pt)	2015-08-25	Composto, prodroga do composto, medicamento, e, uso de um composto.
BR112012002331A2 (pt)	2019-09-24	composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
DK3421471T3 (da)	2021-06-14	Purin- og deazapurinderivater som farmaceutiske forbindelser
BRPI0912356A2 (pt)	2015-10-06	compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
BRPI0811434A2 (pt)	2019-09-24	imidazopiridazinas como inibidores de pi3k lipídeo cinase.
BRPI0813680A2 (pt)	2015-01-06	AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
BRPI0907453A2 (pt)	2015-07-14	Compostos, uso e preparação dos mesmos
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0822337A2 (pt)	2015-06-16	Folatos, composições e usos dos mesmos
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BRPI0914863A2 (pt)	2017-05-30	formulação tópica estável, e, uso da mesma
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
BRPI0810022A2 (pt)	2014-10-14	Álcool alcoxilado, composição, e, uso de um álcool alcoxilado
BRPI0907931A2 (pt)	2015-07-28	Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
BRPI0915134A2 (pt)	2016-02-16	composto, e, uso de um composto
CL2011002041A1 (es)	2012-04-09	Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
CO6300844A2 (es)	2011-07-21	Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
BRPI0913216A2 (pt)	2016-01-19	uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-11-10	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2021-03-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2601 DE 10-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.